Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma

NCT00579566 | Recruiting

• 1 other identifier: 02-060
• Study Type: observational
• Target: 3,000
• Locations: 1 country
• Sites: 7

Brief Summary

The purpose of this study is to study normal and sarcoma cells. To study these cells we need to have human tissue. You will be having or have already had a procedure to remove tissue. We would like to use some of this tissue. We will use it for laboratory studies on the diagnosis,behavior and treatment of sarcoma. We will perform an extensive analysis of your samples. We will only use extra tissue left over after all needed testing has been done or remove an additional small amount of tissue if you are having a biopsy. We will also take blood samples before and/or after your procedure to measure biochemical factors that may help us predict the behavior of sarcoma.

Conditions

Sarcoma

Keywords

Biochemical Determinants; Molecular Determinants

Outcome Measures

Primary Outcomes (1)

• establish and maintain a specimen bank and sarcoma cell line resource

  for laboratory-based studies on the causes, prevention, diagnosis and treatment of human soft tissue sarcoma

  2 years

Secondary Outcomes (1)

• identify new rational therapeutic targets

  2 years

Study Arms (1)

1

Sarcoma patients undergoing core biopsy, incisional biopsy or definitive surgical resection for soft tissue masses of extremity, trunk or retroperitoneum

Other: Specimen protocol

Interventions

Specimen protocol OTHER

The research specimen will be obtained from the residual specimen that would otherwise be discarded per usual hospital procedure.

1

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients seen or referred by Memorial Sloan-Kettering Cancer physicians

You may qualify if:

• All patients with known or suspected sarcoma who will have or have had tissue removed for therapeutic or diagnostic purposes.
• Patients will be entered without preference for any particular racial/ethnic group or gender.
• Patients may have received prior hormonal therapy, cytotoxic chemotherapy, irradiation, immunotherapy or surgical therapy.
• Tissue specimens must be large enough in quantity to allow routine pathologic analysis, with the research laboratory specimen removed from the residual specimen, which would otherwise be discarded. Optimal tissue amounts for snap freeze: Core biopsy - 2 tissue cores Incisional biopsy- 0.5 to 1.5 grams Resected sarcoma specimen- 1.0 to 50 grams depending on size of specimen Normal fat or muscle tissue - 0.5 to 4.0 grams (if available from resected sarcoma specimen) Optimal tissue amounts for RNA later Core biopsy - 2 tissue cores Incisional biopsy- 30 mg (three 3 x 3 x 3 mm cubes) Resected sarcoma specimen - 30 mg (three 3 x 3 x 3 mm cubes) Normal fat or muscle tissue - 30 mg (three 3 x 3 x 3 mm cube

You may not qualify if:

• \- None

Sponsors & Collaborators

• Memorial Sloan Kettering Cancer Center: lead

Study Sites (7)

Memorial Sloan Kettering Basking Ridge (Consent and Follow-Up)

Basking Ridge, New Jersey, 07920, United States

RECRUITING

Memorial Sloan Kettering Monmouth (Consent and Followup)

Middletown, New Jersey, 07748, United States

RECRUITING

Memorial Sloan Kettering Bergen (Consent and Follow up)

Montvale, New Jersey, 07645, United States

RECRUITING

Memorial Sloan Kettering Commack (Consent and Follow-Up)

Commack, New York, 11725, United States

RECRUITING

Memorial Sloan Kettering Westchester (Consent and Followup)

Harrison, New York, 10604, United States

RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

New York, New York, 10065, United States

RECRUITING

Memorial Sloan Kettering Nassau (Consent and Followup)

Rockville Centre, New York, 11553, United States

RECRUITING

Related Links

• Memorial Sloan Kettering Cancer Center

Biospecimen

Retention: SAMPLES WITH DNA

Tissue, Blood

MeSH Terms

Conditions

Sarcoma

Condition Hierarchy (Ancestors)

Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Neoplasms

Study Officials

• Singer Singer, MD

  Memorial Sloan Kettering Cancer Center

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Samuel Singer, MD

CONTACT

212-639-2940

Aimee Crago, MD, PhD

CONTACT

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 19, 2007
• First Posted: December 24, 2007
• Study Start: June 1, 2002
• Primary Completion (Estimated): June 1, 2027
• Study Completion (Estimated): June 1, 2027
• Last Updated: July 30, 2026

Record last verified: 2026-07

Locations

US (7)